Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?

Zhifeng Mao,César Álvarez-Gonzalez,Stefania De Trane,Ozlem Yildiz,Christo Albor, Gabriel Doctor,Derek Soon, George Pepper,Benjamin P Turner,Monica Marta,Joela Mathews,Gavin Giovannoni,David Baker,Klaus Schmierer

Multiple sclerosis journal - experimental, translational and clinical（2018）

引用 8|浏览12

暂无评分

摘要

Our viewpoint takes into account experience we have gathered over the past three years in the use of generic cladribine to treat pwMS. Whilst here we focus on MS, there is significant potential for use of cladribine in other conditions that could benefit from its mechanism of action.

查看译文

关键词

Cladribine,disease-modifying treatment,low- and middle-income countries,multiple sclerosis,off-label

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要